Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioblastoma | 47 | 2024 | 3481 | 4.640 |
Why?
|
Brain Neoplasms | 77 | 2024 | 8863 | 4.340 |
Why?
|
Glioma | 23 | 2023 | 3401 | 1.750 |
Why?
|
Central Nervous System Neoplasms | 8 | 2023 | 895 | 1.610 |
Why?
|
Diffusion Magnetic Resonance Imaging | 7 | 2018 | 2737 | 1.070 |
Why?
|
Quinazolines | 10 | 2017 | 1356 | 1.060 |
Why?
|
Neovascularization, Pathologic | 8 | 2016 | 2635 | 1.050 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2024 | 9239 | 0.830 |
Why?
|
Angiogenesis Inhibitors | 12 | 2021 | 2038 | 0.800 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 11524 | 0.800 |
Why?
|
Capillary Permeability | 2 | 2019 | 798 | 0.790 |
Why?
|
Meningeal Neoplasms | 7 | 2022 | 1241 | 0.790 |
Why?
|
Magnetic Resonance Imaging | 41 | 2023 | 35421 | 0.740 |
Why?
|
Ependymoma | 2 | 2021 | 334 | 0.650 |
Why?
|
Vascular Endothelial Growth Factor A | 8 | 2020 | 3508 | 0.650 |
Why?
|
Antineoplastic Agents | 12 | 2023 | 13695 | 0.650 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 4 | 2017 | 664 | 0.650 |
Why?
|
Diffusion Tensor Imaging | 3 | 2023 | 2305 | 0.630 |
Why?
|
Isocitrate Dehydrogenase | 8 | 2022 | 871 | 0.610 |
Why?
|
Dacarbazine | 6 | 2021 | 566 | 0.610 |
Why?
|
Glutarates | 5 | 2018 | 236 | 0.570 |
Why?
|
Snake Venoms | 1 | 2015 | 39 | 0.530 |
Why?
|
Brain Stem Neoplasms | 1 | 2017 | 204 | 0.500 |
Why?
|
Diagnostic Imaging | 6 | 2022 | 3507 | 0.500 |
Why?
|
Meningioma | 3 | 2022 | 1209 | 0.490 |
Why?
|
Quinolines | 2 | 2016 | 732 | 0.490 |
Why?
|
Anticonvulsants | 3 | 2024 | 1916 | 0.480 |
Why?
|
Positron-Emission Tomography | 9 | 2023 | 6234 | 0.480 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2018 | 627 | 0.470 |
Why?
|
Image Processing, Computer-Assisted | 12 | 2023 | 8949 | 0.450 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 528 | 0.450 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2012 | 1381 | 0.450 |
Why?
|
Cancer Vaccines | 2 | 2017 | 1023 | 0.430 |
Why?
|
Patient Care | 1 | 2018 | 640 | 0.420 |
Why?
|
Magnetic Resonance Spectroscopy | 8 | 2022 | 3760 | 0.420 |
Why?
|
Disease-Free Survival | 14 | 2021 | 6895 | 0.400 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2012 | 640 | 0.380 |
Why?
|
Tumor Microenvironment | 4 | 2022 | 3586 | 0.370 |
Why?
|
Meningeal Carcinomatosis | 2 | 2021 | 65 | 0.370 |
Why?
|
Pyridines | 5 | 2022 | 2825 | 0.370 |
Why?
|
Methotrexate | 4 | 2012 | 1727 | 0.360 |
Why?
|
Humans | 119 | 2024 | 744343 | 0.350 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 85 | 0.350 |
Why?
|
Lymphoma | 3 | 2023 | 1877 | 0.330 |
Why?
|
Oxazines | 2 | 2020 | 298 | 0.320 |
Why?
|
Phthalazines | 1 | 2010 | 363 | 0.310 |
Why?
|
Radiotherapy | 3 | 2010 | 1533 | 0.290 |
Why?
|
Blood-Brain Barrier | 2 | 2016 | 1017 | 0.280 |
Why?
|
Apraxias | 1 | 2007 | 64 | 0.280 |
Why?
|
Infarction, Anterior Cerebral Artery | 1 | 2005 | 12 | 0.270 |
Why?
|
Aphasia | 1 | 2007 | 179 | 0.260 |
Why?
|
Aged | 41 | 2021 | 163280 | 0.250 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2015 | 1770 | 0.250 |
Why?
|
Tremor | 1 | 2005 | 175 | 0.250 |
Why?
|
Brain Edema | 1 | 2009 | 617 | 0.240 |
Why?
|
Adult | 44 | 2024 | 214055 | 0.230 |
Why?
|
Prognosis | 14 | 2020 | 29063 | 0.230 |
Why?
|
Middle Aged | 44 | 2021 | 213383 | 0.230 |
Why?
|
Brain | 20 | 2023 | 26385 | 0.230 |
Why?
|
Combined Modality Therapy | 5 | 2018 | 8642 | 0.210 |
Why?
|
Syncope | 1 | 2005 | 429 | 0.210 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 892 | 0.210 |
Why?
|
Male | 51 | 2021 | 350118 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 5535 | 0.200 |
Why?
|
Contrast Media | 6 | 2020 | 5300 | 0.190 |
Why?
|
Survival Rate | 9 | 2018 | 12788 | 0.190 |
Why?
|
Female | 53 | 2021 | 380194 | 0.190 |
Why?
|
Inositol | 1 | 2021 | 218 | 0.190 |
Why?
|
Craniopharyngioma | 1 | 2023 | 281 | 0.190 |
Why?
|
Hodgkin Disease | 1 | 2008 | 1415 | 0.180 |
Why?
|
Misonidazole | 2 | 2018 | 34 | 0.180 |
Why?
|
Cranial Irradiation | 2 | 2015 | 401 | 0.180 |
Why?
|
Gliosarcoma | 1 | 2020 | 114 | 0.180 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 290 | 0.180 |
Why?
|
Ischemic Attack, Transient | 1 | 2005 | 935 | 0.170 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 85 | 0.170 |
Why?
|
Anilides | 2 | 2019 | 408 | 0.170 |
Why?
|
Valproic Acid | 1 | 2021 | 445 | 0.170 |
Why?
|
Glycine | 1 | 2022 | 671 | 0.160 |
Why?
|
Treatment Outcome | 16 | 2022 | 63114 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 322 | 0.160 |
Why?
|
Spinal Cord Neoplasms | 1 | 2021 | 281 | 0.160 |
Why?
|
Carotid Stenosis | 1 | 2005 | 854 | 0.150 |
Why?
|
Pyrimidines | 2 | 2020 | 2942 | 0.150 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2016 | 1624 | 0.150 |
Why?
|
Angiopoietins | 1 | 2017 | 80 | 0.150 |
Why?
|
Carboplatin | 1 | 2020 | 801 | 0.150 |
Why?
|
Laboratories | 1 | 2021 | 463 | 0.150 |
Why?
|
Spinal Nerve Roots | 1 | 2017 | 121 | 0.150 |
Why?
|
Disease Progression | 7 | 2023 | 13284 | 0.150 |
Why?
|
Vaccines, Subunit | 1 | 2017 | 168 | 0.150 |
Why?
|
Neoplasm Metastasis | 3 | 2020 | 4851 | 0.140 |
Why?
|
Immunity | 1 | 2023 | 1012 | 0.140 |
Why?
|
Postoperative Period | 1 | 2021 | 1842 | 0.140 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 188 | 0.140 |
Why?
|
Blood Vessels | 2 | 2014 | 1125 | 0.140 |
Why?
|
Blood Volume Determination | 1 | 2015 | 43 | 0.130 |
Why?
|
Lithium | 1 | 2019 | 601 | 0.130 |
Why?
|
Seizures | 3 | 2024 | 2859 | 0.130 |
Why?
|
DNA Methylation | 1 | 2009 | 4286 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 10943 | 0.130 |
Why?
|
Diagnostic Tests, Routine | 1 | 2021 | 783 | 0.130 |
Why?
|
Postoperative Care | 2 | 2019 | 1486 | 0.130 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2023 | 2043 | 0.120 |
Why?
|
Mutation | 12 | 2024 | 29786 | 0.120 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 1345 | 0.120 |
Why?
|
Melanoma | 2 | 2023 | 5510 | 0.120 |
Why?
|
Algorithms | 8 | 2024 | 13881 | 0.110 |
Why?
|
Neurosurgical Procedures | 3 | 2024 | 2002 | 0.110 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 973 | 0.110 |
Why?
|
Receptors, CXCR4 | 1 | 2018 | 726 | 0.110 |
Why?
|
Clinical Trials as Topic | 7 | 2022 | 7913 | 0.110 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4933 | 0.110 |
Why?
|
Young Adult | 13 | 2021 | 56430 | 0.110 |
Why?
|
Radiometry | 1 | 2018 | 800 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 3479 | 0.110 |
Why?
|
Dementia | 1 | 2007 | 2518 | 0.110 |
Why?
|
Survival Analysis | 4 | 2021 | 10252 | 0.110 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 903 | 0.110 |
Why?
|
Neurofibromatosis 2 | 1 | 2016 | 380 | 0.110 |
Why?
|
Astrocytoma | 1 | 2017 | 790 | 0.100 |
Why?
|
Radiation Oncology | 1 | 2018 | 555 | 0.100 |
Why?
|
Administration, Oral | 2 | 2017 | 3913 | 0.100 |
Why?
|
Neuroma, Acoustic | 1 | 2016 | 451 | 0.100 |
Why?
|
Follow-Up Studies | 9 | 2018 | 39050 | 0.100 |
Why?
|
src-Family Kinases | 1 | 2014 | 551 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 546 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 4 | 2018 | 4042 | 0.100 |
Why?
|
Bayes Theorem | 2 | 2016 | 2309 | 0.100 |
Why?
|
Aged, 80 and over | 13 | 2021 | 57776 | 0.100 |
Why?
|
Stress, Physiological | 1 | 2019 | 1403 | 0.100 |
Why?
|
Enzyme Inhibitors | 2 | 2020 | 3798 | 0.090 |
Why?
|
Piperazines | 2 | 2021 | 2488 | 0.090 |
Why?
|
Immunotherapy | 2 | 2023 | 4445 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2109 | 0.090 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2016 | 3327 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6538 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 3 | 2024 | 1270 | 0.090 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 178 | 0.090 |
Why?
|
Image Enhancement | 2 | 2018 | 2921 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2020 | 2938 | 0.090 |
Why?
|
Aniline Compounds | 1 | 2014 | 986 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2018 | 2645 | 0.090 |
Why?
|
Epilepsy | 2 | 2024 | 3310 | 0.090 |
Why?
|
Nitriles | 1 | 2014 | 956 | 0.090 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 693 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 648 | 0.090 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2011 | 190 | 0.090 |
Why?
|
Models, Biological | 3 | 2016 | 9583 | 0.080 |
Why?
|
Hearing Loss | 1 | 2016 | 765 | 0.080 |
Why?
|
T-Lymphocytes | 2 | 2023 | 10180 | 0.080 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20822 | 0.080 |
Why?
|
Head | 1 | 2014 | 880 | 0.080 |
Why?
|
Prospective Studies | 5 | 2021 | 53288 | 0.080 |
Why?
|
Autopsy | 2 | 2013 | 1020 | 0.080 |
Why?
|
Nausea | 2 | 2021 | 673 | 0.080 |
Why?
|
Paraneoplastic Syndromes | 2 | 1999 | 151 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4479 | 0.080 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1378 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 552 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 15076 | 0.070 |
Why?
|
Consensus | 3 | 2020 | 2959 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 4 | 2020 | 3772 | 0.070 |
Why?
|
Injections, Spinal | 1 | 2007 | 303 | 0.070 |
Why?
|
Camptothecin | 1 | 2009 | 576 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2018 | 11031 | 0.070 |
Why?
|
Time | 1 | 2008 | 542 | 0.070 |
Why?
|
Alzheimer Disease | 1 | 2007 | 8037 | 0.070 |
Why?
|
Tumor Burden | 2 | 2023 | 1915 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13102 | 0.070 |
Why?
|
Circle of Willis | 1 | 2005 | 68 | 0.070 |
Why?
|
Anterior Cerebral Artery | 1 | 2005 | 48 | 0.070 |
Why?
|
Permeability | 1 | 2007 | 738 | 0.060 |
Why?
|
Neoplasms | 4 | 2021 | 21683 | 0.060 |
Why?
|
Tissue Distribution | 2 | 2020 | 2327 | 0.060 |
Why?
|
Paresis | 1 | 2005 | 179 | 0.060 |
Why?
|
Ultrasonography, Doppler, Transcranial | 1 | 2005 | 292 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12354 | 0.060 |
Why?
|
Child | 4 | 2024 | 77709 | 0.060 |
Why?
|
Perfusion | 2 | 2019 | 1360 | 0.060 |
Why?
|
Benchmarking | 2 | 2024 | 1042 | 0.060 |
Why?
|
Databases, Factual | 1 | 2018 | 7729 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4838 | 0.060 |
Why?
|
Antigens | 2 | 1999 | 1466 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4386 | 0.060 |
Why?
|
Recurrence | 2 | 2020 | 8340 | 0.050 |
Why?
|
Mice, Nude | 2 | 2020 | 3689 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2023 | 77449 | 0.050 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 182 | 0.050 |
Why?
|
Arm | 1 | 2005 | 589 | 0.050 |
Why?
|
Oxygen | 1 | 2013 | 4189 | 0.050 |
Why?
|
Genomics | 3 | 2024 | 5720 | 0.050 |
Why?
|
Autoantibodies | 2 | 2000 | 2035 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 161 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2010 | 1855 | 0.050 |
Why?
|
Antibodies | 1 | 2009 | 2460 | 0.050 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2000 | 23 | 0.050 |
Why?
|
Medical Oncology | 1 | 2012 | 2265 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2017 | 12959 | 0.050 |
Why?
|
Endarterectomy, Carotid | 1 | 2005 | 546 | 0.050 |
Why?
|
Leg | 1 | 2005 | 1116 | 0.050 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2020 | 103 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 227 | 0.040 |
Why?
|
Adolescent | 5 | 2021 | 85781 | 0.040 |
Why?
|
Arginine | 1 | 2022 | 944 | 0.040 |
Why?
|
Antibodies, Neoplasm | 1 | 2000 | 286 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2021 | 13989 | 0.040 |
Why?
|
Genes, myc | 1 | 2020 | 399 | 0.040 |
Why?
|
Causality | 1 | 2005 | 1275 | 0.040 |
Why?
|
Macrophages | 1 | 2013 | 5655 | 0.040 |
Why?
|
DNA Helicases | 1 | 2024 | 859 | 0.040 |
Why?
|
Immune Sera | 1 | 1999 | 641 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1873 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2005 | 1442 | 0.040 |
Why?
|
Functional Laterality | 1 | 2005 | 2290 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2007 | 1620 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2018 | 173 | 0.040 |
Why?
|
Cohort Studies | 5 | 2019 | 40561 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2014 | 2886 | 0.040 |
Why?
|
Motor Cortex | 1 | 2005 | 986 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 538 | 0.040 |
Why?
|
Remission Induction | 1 | 2023 | 2386 | 0.040 |
Why?
|
Lomustine | 1 | 2017 | 59 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 223 | 0.040 |
Why?
|
Ganglia, Spinal | 1 | 2000 | 519 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 249 | 0.040 |
Why?
|
Pattern Recognition, Automated | 1 | 2023 | 1005 | 0.040 |
Why?
|
Automation | 1 | 2019 | 584 | 0.040 |
Why?
|
Vomiting | 1 | 2020 | 636 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 15519 | 0.040 |
Why?
|
Hepatocyte Growth Factor | 1 | 2018 | 270 | 0.040 |
Why?
|
Hypesthesia | 1 | 2017 | 109 | 0.040 |
Why?
|
Exanthema | 1 | 2021 | 501 | 0.040 |
Why?
|
4-1BB Ligand | 1 | 2016 | 29 | 0.030 |
Why?
|
OX40 Ligand | 1 | 2016 | 51 | 0.030 |
Why?
|
Odds Ratio | 1 | 2009 | 9849 | 0.030 |
Why?
|
Phantoms, Imaging | 2 | 2016 | 2480 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1357 | 0.030 |
Why?
|
Peripheral Nervous System | 1 | 2017 | 150 | 0.030 |
Why?
|
Neurons | 3 | 2019 | 9338 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2618 | 0.030 |
Why?
|
Encephalitis | 1 | 1999 | 423 | 0.030 |
Why?
|
Antineoplastic Protocols | 1 | 2015 | 50 | 0.030 |
Why?
|
Preoperative Period | 1 | 2017 | 549 | 0.030 |
Why?
|
Placebos | 1 | 2020 | 1676 | 0.030 |
Why?
|
Brain Mapping | 1 | 2011 | 6669 | 0.030 |
Why?
|
Incidence | 1 | 2013 | 20947 | 0.030 |
Why?
|
Animals | 8 | 2020 | 168757 | 0.030 |
Why?
|
Gadolinium | 1 | 2020 | 952 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2540 | 0.030 |
Why?
|
Physical Phenomena | 1 | 2014 | 46 | 0.030 |
Why?
|
Immunohistochemistry | 4 | 2015 | 11366 | 0.030 |
Why?
|
Signal Transduction | 3 | 2018 | 23403 | 0.030 |
Why?
|
Muscle Weakness | 1 | 2017 | 413 | 0.030 |
Why?
|
Cerebrospinal Fluid | 1 | 2017 | 534 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1531 | 0.030 |
Why?
|
K562 Cells | 1 | 2016 | 634 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 578 | 0.030 |
Why?
|
Skull | 1 | 2018 | 813 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1616 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2007 | 6993 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2010 | 7880 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1061 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2000 | 2025 | 0.030 |
Why?
|
Colitis | 1 | 2021 | 1170 | 0.030 |
Why?
|
Infusions, Intraventricular | 1 | 2012 | 36 | 0.030 |
Why?
|
DNA Modification Methylases | 1 | 2013 | 206 | 0.030 |
Why?
|
Testicular Neoplasms | 1 | 1999 | 804 | 0.030 |
Why?
|
Age Factors | 1 | 2009 | 18370 | 0.030 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2014 | 282 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9274 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3462 | 0.030 |
Why?
|
Neuroblastoma | 1 | 2000 | 1226 | 0.030 |
Why?
|
Transcription Factors | 2 | 2024 | 12208 | 0.030 |
Why?
|
Neuroprotective Agents | 1 | 2019 | 941 | 0.030 |
Why?
|
Microcirculation | 1 | 2016 | 1286 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3778 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2018 | 956 | 0.030 |
Why?
|
Sarcoidosis | 1 | 2017 | 506 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2013 | 349 | 0.030 |
Why?
|
Breast | 1 | 2020 | 1969 | 0.020 |
Why?
|
Reference Standards | 1 | 2015 | 1025 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2020 | 1941 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 934 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1373 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1254 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 16689 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2018 | 5172 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2016 | 2124 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4204 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3527 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2015 | 1641 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2016 | 806 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2416 | 0.020 |
Why?
|
United States | 1 | 2017 | 69872 | 0.020 |
Why?
|
Brain Diseases | 1 | 1999 | 1563 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2015 | 1462 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2016 | 1534 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2024 | 5853 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2011 | 712 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2727 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4201 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2015 | 1372 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 2017 | 1848 | 0.020 |
Why?
|
Sirolimus | 1 | 2014 | 1564 | 0.020 |
Why?
|
Piperidines | 1 | 2014 | 1602 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3870 | 0.020 |
Why?
|
Hemodynamics | 1 | 2016 | 4199 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 1999 | 4462 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12026 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1660 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15997 | 0.020 |
Why?
|
Gene Expression | 1 | 2018 | 7799 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5524 | 0.020 |
Why?
|
Tuberculosis | 1 | 2017 | 1912 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12245 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6171 | 0.010 |
Why?
|
Vaccination | 1 | 2016 | 3278 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 2849 | 0.010 |
Why?
|
Computer Simulation | 1 | 2016 | 6196 | 0.010 |
Why?
|
Rats | 4 | 2000 | 24260 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4026 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 5974 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 20129 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8428 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 21746 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2018 | 25625 | 0.010 |
Why?
|
Models, Statistical | 1 | 2016 | 5102 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2012 | 2219 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 16718 | 0.010 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2000 | 9 | 0.010 |
Why?
|
Receptors, Purinergic P2X2 | 1 | 2000 | 9 | 0.010 |
Why?
|
Infant | 2 | 2018 | 35136 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6756 | 0.010 |
Why?
|
Child, Preschool | 2 | 2018 | 41006 | 0.010 |
Why?
|
Electric Conductivity | 1 | 2000 | 411 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 9959 | 0.010 |
Why?
|
Receptors, Purinergic P2 | 1 | 2000 | 153 | 0.010 |
Why?
|
Purkinje Cells | 1 | 2000 | 224 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19905 | 0.010 |
Why?
|
Limbic System | 1 | 1999 | 426 | 0.010 |
Why?
|
Apoptosis | 1 | 2012 | 9727 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1999 | 2050 | 0.010 |
Why?
|
Brain Chemistry | 1 | 1999 | 981 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2000 | 1537 | 0.010 |
Why?
|
Testis | 1 | 1999 | 803 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2012 | 11483 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 23338 | 0.010 |
Why?
|
Glutamic Acid | 1 | 2000 | 1169 | 0.010 |
Why?
|
Brain Stem | 1 | 1999 | 846 | 0.010 |
Why?
|
Drug Resistance | 1 | 2000 | 1609 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1999 | 13033 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2000 | 1701 | 0.010 |
Why?
|
Cerebellum | 1 | 2000 | 1488 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1999 | 4320 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81183 | 0.010 |
Why?
|
Blotting, Western | 1 | 2000 | 5179 | 0.010 |
Why?
|
Epitopes | 1 | 1999 | 2571 | 0.010 |
Why?
|
Kinetics | 1 | 2000 | 6473 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 1999 | 1988 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2000 | 4560 | 0.000 |
Why?
|
Base Sequence | 1 | 1999 | 12797 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 13815 | 0.000 |
Why?
|
Hippocampus | 1 | 1999 | 3675 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1999 | 18111 | 0.000 |
Why?
|
Cerebral Cortex | 1 | 2000 | 5708 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2000 | 19229 | 0.000 |
Why?
|
Time Factors | 1 | 2000 | 40075 | 0.000 |
Why?
|